Navigation Links
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
Date:5/15/2009

program for ENMD-2076 is expanding with the addition of the myeloma clinical study announced earlier and with this new study in patients with leukemia. Also, plans are underway to expand the solid tumor study at the maximum tolerated dose of ENMD-2076 to further define the objectives of safety, pharmacokinetics and antitumor activity. We believe the current clinical program allows us to quickly add new patients to establish the potential of ENMD-2076 and provide a focus for Phase 2 development. These data serve as a foundation to continue discussions with potential development partners for ENMD-2076."

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrate significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to Aurora A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 targets a defined set of kinases, including Flt-3 and FGFR3, which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
2. EntreMed to Present at the New York Society of Security Analysts Industry Conference
3. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
4. EntreMed Reports Third Quarter 2008 Financial Results
5. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
6. EntreMed to Present at BioPartnering Europe Conference
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. EntreMed Reports Second Quarter 2008 Financial Results
9. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
10. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... SAN FRANCISCO, March 16 Medivation, Inc. (Nasdaq: ... and financial results for the fourth quarter and year ended December ... to an equally exciting 2009. We have made excellent progress across ... testing in all of our programs in 2009 -- Dimebon in ...
... 16 TauTaTis, Inc. announces that its lead compound ... process in Alzheimer,s Disease, has been recognized as the ... Disease gene LRRK2 reported to date. Mutations of ... are the most genetic frequent cause of Parkinson,s Disease.TauTaTis, ...
... Provider, Offers Traceability Down to the Unit Level to Secure ... ... Southborough, MA (PRWEB) March 16, 2009 -- PHARMORX ... technology services provider, today announced the availability of its new ...
Cached Biology Technology:Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 2Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 3Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 4Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 5Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 6Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 7Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 8TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 3
(Date:4/15/2014)... CLEVELAND, Ohio (April 16, 2014)A new study from the ... vitamin D levels and menopause symptoms. The study was ... of The North American Menopause Society., The authors analyzed ... and a number of menopause symptoms, including hot flashes, ... women who participated in the calcium and vitamin D ...
(Date:4/15/2014)... in Greenbelt, Md., is home to hundreds of ... Goddard, some of the most cutting-edge Earth science ... that cutting-edge innovation has earned a Goddard scientist ... for Anthropology and Geography awards the Vega Medal ... shown excellence in the fields of physical geography, ...
(Date:4/15/2014)... Missouri researchers have previously shown that a genetic pre-disposition ... In a new study, Frank Booth, a professor in ... potential link between the genetic pre-disposition for high levels ... maturation occurs. , For his study, Booth selectively bred ... extreme laziness. Booth then put the rats in cages ...
Breaking Biology News(10 mins):Low Vitamin D may not be a culprit in menopause symptoms 2Goddard scientist receives Vega Medal from King of Sweden 2Genetic pre-disposition toward exercise and mental development may be linked 2
... dreaded disease in medieval Europe ?to fade from the ... disappeared there. , The reason seems to be, say ... London, that tuberculosis, a far more deadly disease, overtook ... based upon the examination of DNA from human remains ...
... Throughout the animal kingdom, rival males routinely challenge one ... collisions between bighorn rams to the ritualized wrestling matches ... reproductive success. , But now scientists studying a ... male cichlids can quickly become leading men without even ...
... provide some protection to the heart from injury even ... heart attack, Jefferson Medical College researchers report. , Walter ... in the Department of Medicine at Jefferson Medical College ... knew that the drug Darbepoietin alpha would protect the ...
Cached Biology News:Once-dreaded leprosy 'replaced' by tuberculosis, say researchers 2Sudden change in social status triggers genetic response in male fish, study finds 2Sudden change in social status triggers genetic response in male fish, study finds 3Sudden change in social status triggers genetic response in male fish, study finds 4Sudden change in social status triggers genetic response in male fish, study finds 5Sudden change in social status triggers genetic response in male fish, study finds 6
... end-users to be "a delight to use" ... microscopy and electronic imaging. With its ergonomic ... require much space and can easily be ... DM-BA300 combines Motic's own revolutionary Colour Corrected ...
Request Info...
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: